{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:23:18Z","timestamp":1792783398523,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"MSD China","id":[{"id":"https:\/\/ror.org\/01hr8kn45","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03732-y","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:31:37Z","timestamp":1790605897000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient Characteristics and Treatment Patterns of Advanced Biliary Tract Cancer (BTC): A Chinese Physician Survey"],"prefix":"10.1007","author":[{"given":"Hui","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenmin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyi","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"issue":"6","key":"3732_CR1","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1053\/j.gastro.2013.10.013","volume":"145","author":"SI Ilyas","year":"2013","unstructured":"Ilyas SI, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013;145(6):1215\u201329.","journal-title":"Gastroenterology"},{"issue":"9","key":"3732_CR2","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557\u201388.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"3732_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1470-7330-14-14","volume":"14","author":"TP Hennedige","year":"2014","unstructured":"Hennedige TP, Neo WT, Venkatesh SK. Imaging of malignancies of the biliary tract- an update. Cancer Imaging. 2014;14(1):14.","journal-title":"Cancer Imaging"},{"issue":"10272","key":"3732_CR4","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021;397(10272):428\u201344.","journal-title":"Lancet"},{"issue":"22","key":"3732_CR5","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1016\/j.scib.2024.09.026","volume":"69","author":"W Zhang","year":"2024","unstructured":"Zhang W, Wang YJ, Liu JM, et al. Burden of biliary tract carcinoma in China (1990\u20132021): findings from the 2021 Global Burden of Disease Study. Sci Bull (Beijing). 2024;69(22):3547\u201357.","journal-title":"Sci Bull (Beijing)"},{"issue":"2","key":"3732_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","volume":"34","author":"A Vogel","year":"2023","unstructured":"Vogel A, Bridgewater J, Edeline J, et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(2):127\u201340.","journal-title":"Ann Oncol"},{"issue":"14","key":"3732_CR7","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u201381.","journal-title":"N Engl J Med"},{"issue":"10","key":"3732_CR8","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1007\/s00535-020-01712-9","volume":"55","author":"C Xie","year":"2020","unstructured":"Xie C, McGrath NA, Monge Bonilla C, Fu J. Systemic treatment options for advanced biliary tract carcinoma. J Gastroenterol. 2020;55(10):944\u201357.","journal-title":"J Gastroenterol"},{"issue":"8","key":"3732_CR9","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","volume":"9","author":"DY Oh","year":"2024","unstructured":"Oh DY, He AR, Bouattour M, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase\u00a03 study. Lancet Gastroenterol Hepatol. 2024;9(8):694\u2013704.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10391","key":"3732_CR10","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase\u00a03 trial. Lancet. 2023;401(10391):1853\u201365.","journal-title":"Lancet"},{"key":"3732_CR11","doi-asserted-by":"crossref","unstructured":"Shi H, Fan M, Zhang H, et al. Perceived health-care quality in China: a comparison of second- and third-tier hospitals. Int J Qual Health Care. 2021;33(1);mzab027.","DOI":"10.1093\/intqhc\/mzab027"},{"issue":"5","key":"3732_CR12","doi-asserted-by":"publisher","first-page":"474","DOI":"10.21147\/j.issn.1000-9604.2024.05.02","volume":"36","author":"J Zhou","year":"2024","unstructured":"Zhou J, Tan G, Zhang L, et al. Epidemiology of biliary tract cancer in China: a narrative review. Chin J Cancer Res. 2024;36(5):474\u201388.","journal-title":"Chin J Cancer Res"},{"issue":"19","key":"3732_CR13","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1097\/CM9.0000000000003258","volume":"137","author":"X Wang","year":"2024","unstructured":"Wang X, Bai Y, Chai N, et al. Chinese national clinical practice guideline on diagnosis and treatment of biliary tract cancers. Chin Med J (Engl). 2024;137(19):2272\u201393.","journal-title":"Chin Med J (Engl)"},{"key":"3732_CR14","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Biliary Tract Cancers Version 1.2025. 2025."},{"key":"3732_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114199","volume":"208","author":"M Rimini","year":"2024","unstructured":"Rimini M, Fornaro L, Rizzato MD, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: a large real-life worldwide population. Eur J Cancer. 2024;208:114199.","journal-title":"Eur J Cancer"},{"issue":"8","key":"3732_CR16","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1111\/liv.15641","volume":"43","author":"M Rimini","year":"2023","unstructured":"Rimini M, Fornaro L, Lonardi S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: an early exploratory analysis of real-world data. Liver Int. 2023;43(8):1803\u201312.","journal-title":"Liver Int"},{"issue":"6","key":"3732_CR17","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.21037\/jgo-20-562","volume":"11","author":"D Sun","year":"2020","unstructured":"Sun D, Ma J, Wang J, et al. A real-world study of the efficacy and safety of anti-programmed cell death-1 therapy combined with chemotherapy or targeted therapy in patients with advanced biliary tract cancer. J Gastrointest Oncol. 2020;11(6):1421\u201330.","journal-title":"J Gastrointest Oncol"},{"issue":"1","key":"3732_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/ajco.12592","volume":"13","author":"K Park","year":"2017","unstructured":"Park K, Kim KP, Park S, Chang HM. Comparison of gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer. Asia Pac J Clin Oncol. 2017;13(1):13\u201320.","journal-title":"Asia Pac J Clin Oncol"},{"key":"3732_CR19","unstructured":"Branch of Biliary Surgery\/Chinese Society of Surgery \/ Chinese Medical Association, Working Group of Biliary Surgeons\/Chinese College of Surgeons \/ Chinese Medical Doctor Association. [Expert consensus on conversion therapy of biliary tract cancer (2025)]. Zhonghua Wai Ke Za Zhi. 2025;63(6):453\u201360."},{"issue":"1","key":"3732_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2020.100614","volume":"45","author":"M Fruscione","year":"2021","unstructured":"Fruscione M, Pickens RC, Baker EH, et al. Conversion therapy for intrahepatic cholangiocarcinoma and tumor downsizing to increase resection rates: a systematic review. Curr Probl Cancer. 2021;45(1):100614.","journal-title":"Curr Probl Cancer"},{"issue":"1","key":"3732_CR21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.14701\/ahbps.2020.24.1.6","volume":"24","author":"S Kamarajah","year":"2020","unstructured":"Kamarajah S, Giovinazzo F, Roberts KJ, et al. The role of down staging treatment in the management of locally advanced intrahepatic cholangiocarcinoma: review of literature and pooled analysis. Ann Hepatobiliary Pancreat Surg. 2020;24(1):6\u201316.","journal-title":"Ann Hepatobiliary Pancreat Surg"},{"issue":"8","key":"3732_CR22","doi-asserted-by":"publisher","first-page":"4608","DOI":"10.1097\/JS9.0000000000001540","volume":"110","author":"S Wang","year":"2024","unstructured":"Wang S, Wang Y, Zhu C, et al. Conversion surgery intervention versus continued systemic therapy in patients with a response after PD-1\/PD-L1 inhibitor-based combination therapy for initially unresectable biliary tract cancer: a retrospective cohort study. Int J Surg. 2024;110(8):4608\u201316.","journal-title":"Int J Surg"},{"issue":"5","key":"3732_CR23","doi-asserted-by":"publisher","first-page":"772","DOI":"10.21037\/hbsn-23-352","volume":"12","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Zhang W. Conversion therapy for advanced cholangiocarcinoma in the era of molecular targeted therapy and immune therapy. Hepatobiliary Surg Nutr. 2023;12(5):772\u20135.","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"3","key":"3732_CR24","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00595-024-02912-z","volume":"55","author":"H Kosaka","year":"2025","unstructured":"Kosaka H, Matsui K, Ikeura T, et al. Prognostic impact of combination therapy with gemcitabine and cisplatin plus S-1 and subsequent conversion surgery for initially unresectable upper biliary tract cancers. Surg Today. 2025;55(3):351\u20139.","journal-title":"Surg Today"},{"key":"3732_CR25","doi-asserted-by":"publisher","DOI":"10.1177\/11795549241272469","volume":"18","author":"H Weng","year":"2024","unstructured":"Weng H, Zeng P, Chen Y, Xu Q, Ying J. An active trend of immunotherapy combination regimen as second-line therapy towards advanced biliary tract cancer. Clin Med Insights Oncol. 2024;18:11795549241272469.","journal-title":"Clin Med Insights Oncol"},{"key":"3732_CR26","doi-asserted-by":"publisher","DOI":"10.1177\/11795549251317012","volume":"19","author":"C Jiang","year":"2025","unstructured":"Jiang C, Yang L, Kong LY, et al. Comparing immunotherapy versus chemotherapy alone as second-line therapy for malignant tumors of the biliary tract: a retrospective study. Clin Med Insights Oncol. 2025;19:11795549251317012.","journal-title":"Clin Med Insights Oncol"},{"key":"3732_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmogo.2024.100055","volume":"4","author":"A Digklia","year":"2024","unstructured":"Digklia A, Arnold D, Voutsadakis IA. Second-line FOLFOX chemotherapy for patients with advanced biliary tract cancers pretreated with cisplatin\/gemcitabine: a systematic review and meta-analysis. ESMO Gastrointest Oncol. 2024;4:100055.","journal-title":"ESMO Gastrointest Oncol"},{"issue":"1150","key":"3732_CR28","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20230079","volume":"96","author":"Z Ning","year":"2023","unstructured":"Ning Z, Xie L, Yan X, et al. Transarterial chemoembolization plus lenvatinib with or without a PD-1 inhibitor for advanced and metastatic intrahepatic cholangiocarcinoma: a retrospective real-world study. Br J Radiol. 2023;96(1150):20230079.","journal-title":"Br J Radiol"},{"issue":"3","key":"3732_CR29","first-page":"1026","volume":"13","author":"Y Wang","year":"2023","unstructured":"Wang Y, Xun Z, Yang X, et al. Local-regional therapy combined with toripalimab and lenvatinib in patients with advanced biliary tract cancer. Am J Cancer Res. 2023;13(3):1026\u201337.","journal-title":"Am J Cancer Res"},{"key":"3732_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15071970","author":"MM Queiroz","year":"2023","unstructured":"Queiroz MM, Lima NF Jr., Biachi de Castria T. Immunotherapy and targeted therapy for advanced biliary tract cancer: adding new flavors to the pizza. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15071970.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"3732_CR31","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/cncr.11699","volume":"98","author":"WR Jarnagin","year":"2003","unstructured":"Jarnagin WR, Ruo L, Little SA, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma. Cancer. 2003;98(8):1689\u2013700.","journal-title":"Cancer"},{"issue":"4","key":"3732_CR32","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.surg.2017.08.011","volume":"163","author":"K Komaya","year":"2018","unstructured":"Komaya K, Ebata T, Yokoyama Y, et al. Recurrence after curative-intent resection of perihilar cholangiocarcinoma: analysis of a large cohort with a close postoperative follow-up approach. Surgery. 2018;163(4):732\u20138.","journal-title":"Surgery"},{"issue":"S1","key":"3732_CR33","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/liv.14089","volume":"39","author":"U Cillo","year":"2019","unstructured":"Cillo U, Fondevila C, Donadon M, et al. Surgery for cholangiocarcinoma. Liver Int. 2019;39(S1):143\u201355.","journal-title":"Liver Int"},{"issue":"7","key":"3732_CR34","doi-asserted-by":"publisher","first-page":"4967","DOI":"10.1245\/s10434-025-17156-5","volume":"32","author":"J Kawashima","year":"2025","unstructured":"Kawashima J, Endo Y, Woldesenbet S, et al. Recurrence-free survival as a surrogate for overall survival among patients with intrahepatic cholangiocarcinoma following upfront surgery: an international multi-institutional analysis. Ann Surg Oncol. 2025;32(7):4967\u201375.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"3732_CR35","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41392-020-00324-2","volume":"5","author":"X Song","year":"2020","unstructured":"Song X, Hu Y, Li Y, et al. Overview of current targeted therapy in gallbladder cancer. Signal Transduct Target Ther. 2020;5(1):230.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"3732_CR36","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.livres.2024.11.005","volume":"8","author":"A Ainiwaer","year":"2024","unstructured":"Ainiwaer A, Cheng J, Lang R, et al. Chinese expert consensus on the clinical application of molecular diagnostics in hepatobiliary cancers (2024 edition). Liver Res. 2024;8(4):195\u2013206.","journal-title":"Liver Res"},{"issue":"5","key":"3732_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2026.101777","volume":"8","author":"AD Wagner","year":"2026","unstructured":"Wagner AD, Lopes A, Chambers P, et al. Impact of sex on chemotherapy toxicity and efficacy in biliary tract cancer: analysis of ABC, BILCAP trials and population data. JHEP Rep. 2026;8(5):101777.","journal-title":"JHEP Rep"},{"key":"3732_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmogo.2025.100262","volume":"10","author":"A Markussen","year":"2025","unstructured":"Markussen A, Christensen TD, Kaerlev L, et al. Real-world treatment patterns and outcomes in biliary tract cancer: a Danish retrospective cohort study. ESMO Gastrointest Oncol. 2025;10:100262.","journal-title":"ESMO Gastrointest Oncol"},{"issue":"14","key":"3732_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17142301","volume":"17","author":"K Gaston","year":"2025","unstructured":"Gaston K, Mohammad A, Venkatachalapathy SV, et al. Challenges in the diagnosis of biliary stricture and cholangiocarcinoma and perspectives on the future applications of advanced technologies. Cancers (Basel). 2025;17(14):2301.","journal-title":"Cancers (Basel)"},{"issue":"13","key":"3732_CR40","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1016\/j.ejca.2015.05.018","volume":"51","author":"A Lamarca","year":"2015","unstructured":"Lamarca A, Benafif S, Ross P, Bridgewater J, Valle JW. Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: effective intervention in patients with luminal disease. Eur J Cancer. 2015;51(13):1694\u2013703.","journal-title":"Eur J Cancer"},{"issue":"1","key":"3732_CR41","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1136\/gutjnl-2023-330029","volume":"73","author":"SM Rushbrook","year":"2023","unstructured":"Rushbrook SM, Kendall TJ, Zen Y, et al. British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma. Gut. 2023;73(1):16\u201346.","journal-title":"Gut"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03732-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03732-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03732-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:54:29Z","timestamp":1790654069000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03732-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":41,"alternative-id":["3732"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03732-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"14 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Wenting Chen and Wenmin Tang are employees of MSD China. Hui Qiu, Qiao Liu, Zhen Wang, and Chunyi Hao have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Medical Ethics Committee of Beijing Cancer Hospital (approval no.\u00a02024YJZ74) and registered in the Chinese Clinical Trial Registry (ChiCTR2400087092). All physicians provided written, informed consent prior to inclusion in the study, no patient consent was required as patient data were not collected.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}